Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: A proposal

Histopathology

Volumn 65, Issue 2, 2014, Pages 149-154

  Singh, Naveena ^a   Gilks, C Blake ^b   Wilkinson, Nafisa ^c   Mccluggage, W Glenn ^d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Diagnosis; High grade serous carcinoma; Ovary; Primary site; Staging

Indexed keywords

CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CLINICAL PRACTICE; HUMAN; INVASIVE CARCINOMA; OVARY CARCINOMA; PATHOLOGIST; PERITONEAL CARCINOMA; PERITONEUM CANCER; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; UTERINE TUBE; CARCINOMA; CYSTADENOCARCINOMA; FEMALE; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; UTERINE TUBE TUMOR;

CARCINOMA; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84904400814     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12419     Document Type: Review

References (33)

1. Prat J; for the FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. 2014; 124; 1-5.
2. Lee KR, Tavassoli FA, Prat J et al. Tumours of the ovary and peritoneum. In Tavassoli FA, Devilee P eds. World Health Organization classification of tumours: tumours of the breast and female genital organs. Lyon: IARC Press, 2003; 116.
3. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLOS Med. 2008; 5; e232.
4. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011; 43; 420-432.
5. Gurung A, Hung T, Morin J, Gilks CB. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 2013; 62; 59-70.
6. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 2001; 25; 1283-1289.
7. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001; 195; 451-456.
8. Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006; 30; 230-236.
9. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007; 31; 161-169.
10. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of ovarian and fallopian tube mucosal serous carcinoma. Gynecol. Oncol. 2008; 110; 408-417.
11. Tang S, Onuma K, Deb P et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int. J. Gynecol. Pathol. 2012; 31; 103-110.
12. Carlson JW, Miron A, Jarboe EA et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 2008; 26; 4160-4165.
13. Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis. J. Pathol. 2010; 220; 5-6.
14. Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih IeM. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am. J. Surg. Pathol. 2010; 34; 829-836.
15. Kuhn E, Bahadirli-Talbot A, Kurman R, Sehdev AS, Wang T-L, Shih I-M. CCNE1 amplification may precede centrosome number abnormality in progression from serous tubal intraepithelial carcinoma to high-grade serous carcinoma. Mod. Pathol. 2013; 26(Suppl. 2); 283A.
16. Garg K, Rabban J. Practical value of systematic and complete examination of fallopian tubes in unselected women undergoing salpingectomy for benign indications: results of a prospective study. Mod. Pathol. 2013; 26(Suppl. 2); 276A.
17. Rabban JT, Vohra P, Zaloudek C. Intramucosal growth in fallopian tube fimbriae by tumors of non-gynecologic origin may mimic serous tubal intraepithelial carcinoma and tubal mucinous metaplasia. Mod. Pathol. 2014; 27(Suppl. 2); 302A.
18. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am. J. Surg. Pathol. 2010; 34; 1407-1416.
19. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004; 23; 41-44.
20. Köbel M, Kalloger SE, Huntsman DG et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 2010; 29; 203-211.
21. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474; 609-615.
22. The Cancer Genome Atlas Research Network. Integrated genomic analyses of endometrial carcinoma. Nature 2013; 497; 67-73.
23. McConechy MK, Anglesio MS, Kalloger SE et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J. Pathol. 2011; 223; 567-573.
24. Carlson JW, Jarboe EA, Kindelberger D et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int. J. Gynecol. Pathol. 2010; 29; 310-314.
25. Visvanathan K, Vang R, Shaw P et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am. J. Surg. Pathol. 2011; 35; 1766-1775.
26. Vang R, Visvanathan K, Gross A et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int. J. Gynecol. Pathol. 2012; 31; 243-253.
27. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube and peritoneum. Int. J. Gynecol. Obstet. 2012; 119S; S118-S129.
28. Jarboe EA, Miron A, Carlson JW et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int. J. Gynecol. Pathol. 2009; 28; 308-315.
29. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int. J. Gynecol. Pathol. 2004; 23; 97-99.
30. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int. J. Gynecol. Pathol. 2000; 19; 158-163.
31. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44; 109-115.
32. Wethington SL, Park KJ, Soslow RA et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int. J. Gynecol. Cancer 2013; 23; 1603-1611.
33. Bloss JD, Liao S, Buller RE et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol. Oncol. 1993; 50; 347-351.